Cargando…

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Detalles Bibliográficos
Autores principales:	Harvey, Christopher, Elpek, Kutlu, Duong, Ellen, Simpson, Tyler, Shu, ChengYi J, Shallberg, Lindsey, Wallace, Matthew, Sathyanarayanan, Sriram, Mabry, Robert, Briskin, Michael, Michaelson, Jennifer, Gajewski, Thomas F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/ http://dx.doi.org/10.1186/2051-1426-3-S2-O9

Ejemplares similares

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
por: Hanson, Amanda, et al.
Publicado: (2020)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

Dissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H4 and PD-L1
por: Shaffer, Donald R, et al.
Publicado: (2015)

Rational combinations of immunotherapeutics that target discrete pathways
por: Spranger, Stefani, et al.
Publicado: (2013)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
por: Martinez, Alejandra, et al.
Publicado: (2020)

Role of endocytosis and trans‐endocytosis in ICOS costimulator‐induced downmodulation of the ICOS Ligand
por: Aragoneses‐Fenoll, Laura, et al.
Publicado: (2021)

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo
por: Corrales, Leticia, et al.
Publicado: (2013)

ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain
por: O’Brien, Carleigh A., et al.
Publicado: (2020)

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
por: Rujas, Edurne, et al.
Publicado: (2020)

Regulation of T follicular helper cells by ICOS
por: Hutloff, Andreas
Publicado: (2015)

ICOS regulates ILC2s in asthma
por: Maazi, Hadi, et al.
Publicado: (2015)

ICOS Co-Stimulation: Friend or Foe?
por: Wikenheiser, Daniel J., et al.
Publicado: (2016)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

K20 and ICO-10 monoclonal antibodies (gp120/200; Thy-1): immunophenotyping of human solid tumours.
por: Kadagidze, Z. G., et al.
Publicado: (1990)

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
por: Yap, Timothy A., et al.
Publicado: (2022)

Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development
por: Abozeid, Mohamed, et al.
Publicado: (2017)

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
por: Orvain, Cindy, et al.
Publicado: (2022)

Tokenomics: the crypto shift of blockchains, ICOs, and tokens
por: Au, Sean, et al.
Publicado: (2018)

International trends in optics and photonics: ICO IV
por: Asakura, Toshimitsu
Publicado: (1999)

Computational vaccinology and the ICoVax 2012 workshop
por: He, Yongqun, et al.
Publicado: (2013)

S-nitrosoglutathione modulates CXCR4 and ICOS expression
por: Yamamoto, Yoshihiko, et al.
Publicado: (2006)

The ICOS–ICOSL pathway tunes thymic selection
por: Dong, Mengqi, et al.
Publicado: (2022)

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
por: Chary, Michael, et al.
Publicado: (2023)

Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
por: Yun, Chae-Ok, et al.
Publicado: (2022)

ICOS Gene Polymorphisms (IVS1 + 173 T/C and c. 1624 C/T) in Primary Sjögren’s Syndrome Patients: Analysis of ICOS Expression
por: García-Espinoza, José Antonio, et al.
Publicado: (2022)

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy
por: Sharma, Rajesh Kumar, et al.
Publicado: (2010)

The clinical impact of ICOS signal in colorectal cancer patients
por: Zhang, Yan, et al.
Publicado: (2016)

Initial coin offerings (ICOs): Why do they succeed?
por: Campino, José, et al.
Publicado: (2022)

Transcriptome profile and clinical characterization of ICOS expression in gliomas
por: Wang, Jin, et al.
Publicado: (2022)

ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells
por: Panneton, Vincent, et al.
Publicado: (2023)

Pilot Study of Delayed ICOS/ICOS-L Blockade With αCD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model
por: O’Neill, Natalie A., et al.
Publicado: (2018)

Targeting the ICOS/ICOS‐L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease
por: Uwadiae, Faith I., et al.
Publicado: (2018)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
por: DeNardo, David G, et al.
Publicado: (2021)

ICOS deficiency hampers the homeostasis, development and function of NK cells
por: Montes-Casado, María, et al.
Publicado: (2019)

What Key Aspects Do ICOs Reveal About Their Businesses?
por: Laatikainen, Gabriella, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b1l1ghgmgvnsdhe4h9qubvq5bf